4785 Medroxyprogesterone Acetate Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17‘±-hydroxy-6‘±-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. 71-58-9 6279 C24H34O4 White powder. 214.5°C 22.2mg/L Rapidly absorbed from GI tract Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge. Hepatic. Route of Elimination: Following oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates. Half Life: 50 days 2B, possibly carcinogenic to humans. (L135) Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens. Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders. 2014-09-11T05:13:46Z 2026-03-27T00:47:19Z Medroxyprogesterone C08150 6715 DB00603 true [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C C24H34O4 InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1 PSGAAPLEWMOORI-PEINSRQWSA-N 386.5244 386.245709576 Exogenous Solid 3.5 CHEMBL717 6043 <p>Klaus <span class="caps">ANNEN</span>, Thomas Linz, Karl-Heinz Neff, Rolf Bohlmann, Henry Laurent, &#8220;<span class="caps">PROCESS</span> <span class="caps">FOR</span> <span class="caps">PREPARING</span> 17ALPHA-<span class="caps">ACETOXY</span>-6-<span class="caps">METHYLENEPREGN</span>-4-<span class="caps">ENE</span>-3,20-<span class="caps">DIONE</span>, <span class="caps">MEDROXYPROGESTERONE</span> <span class="caps">ACETATE</span> <span class="caps">AND</span> <span class="caps">MEGESTROL</span> <span class="caps">ACETATE</span>.&#8221; U.S. Patent US20090012321, issued January 08, 2009.</p> CHEM003687 DTXSID0025527 NS00006415 (1S,2R,8S,10R,11S,14R,15S)-14-acetyl-2,8,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl acetate